Skip to main content

Advertisement

SpringerLink
Log in

Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Cancer patients with long-term venous catheter are at risk for thromboembolic complications at the catheter tip and in the adjacent venous vessels. We assessed whether local thrombogenicity could be prevented with an experimental coated (with athrombogenic layer) catheter device (CD) compared to an uncoated CD. Patients requiring a long-term venous catheter were randomly allocated to receive either a standard uncoated or experimental coated (with athrombogenic Camouflage® layer) CD. The athrombogenic layer creates a barrier against non-specific adsorption of plasma proteins. The primary endpoint was urokinase injection in cases of an unsuccessful blood aspiration from the CD. Secondary endpoints included early (haematoma, pneumothorax) and late (venous thrombosis, infection) catheter-associated complications and catheter defects. One hundred and seventy-nine patients were randomly assigned to a CD (experimental n = 89/standard n = 90). One hundred and ten (62%) patients with a total of 1,286 catheter taps were analysed for the primary endpoint. Necessity for urokinase injection was 8/680 (1.2% experimental) vs. 33/606 (5.4% standard) per catheter tap and 4/55 (7.3% experimental) vs. 18/55 (32.7% standard) per patient. A repeated measures logistic regression to assess the effect of coating yielded an odds ratio of 3.5 (95% confidence interval, 1.2–10.4; p = 0.03) for the primary endpoint. All patients allocated per protocol were analysed for the secondary endpoints. Nine (5.4%) local thrombotic complications, seven (4.1%) catheter infections, and no catheter defect were observed. Athrombogenic coating of CD in cancer patients resulted in a significant reduced necessity for urokinase injections and subsequently less inconvenience for patients and fewer costly interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Vescia S, Baumgartner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S et al (2008) Management of venous port systems in oncology: a review of current evidence. Ann Oncol 19(1):9–15

    Article  PubMed  CAS  Google Scholar 

  2. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400S

    Article  PubMed  CAS  Google Scholar 

  3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809–815

    Article  PubMed  CAS  Google Scholar 

  4. Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87(4):575–579

    PubMed  CAS  Google Scholar 

  5. Thodiyil PA, Kakkar AK (2002) Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87(6):1076–1077

    PubMed  CAS  Google Scholar 

  6. Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9(2):286–294

    PubMed  CAS  Google Scholar 

  7. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W et al (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318(7):404–407

    Article  PubMed  CAS  Google Scholar 

  8. Yildizeli B, Lacin T, Batirel HF, Yuksel M (2004) Complications and management of long-term central venous access catheters and ports. J Vasc Access 5(4):174–178

    PubMed  CAS  Google Scholar 

  9. De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S et al (1997) Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 86(2):101–113

    Article  PubMed  Google Scholar 

  10. Pottecher T, Forrler M, Picardat P, Krause D, Bellocq JP, Otteni JC (1984) Thrombogenicity of central venous catheters: prospective study of polyethylene, silicone and polyurethane catheters with phlebography or post-mortem examination. Eur J Anaesthesiol 1(4):361–365

    PubMed  CAS  Google Scholar 

  11. Xiang DZ, Verbeken EK, Van Lommel AT, Stas M, De Wever I (1998) Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg 28(2):260–271

    Article  PubMed  CAS  Google Scholar 

  12. Martin C, Viviand X, Saux P, Gouin F (1999) Upper-extremity deep vein thrombosis after central venous catheterization via the axillary vein. Crit Care Med 27(12):2626–2629

    Article  PubMed  CAS  Google Scholar 

  13. Mehall JR, Saltzman DA, Jackson RJ, Smith SD (2002) Fibrin sheath enhances central venous catheter infection. Crit Care Med 30(4):908–912

    Article  PubMed  Google Scholar 

  14. Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404–413

    Article  Google Scholar 

  15. Cook RJSD (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310:452–454

    Article  PubMed  CAS  Google Scholar 

  16. Lyon RD, Griggs KA, Johnson AM, Olsen JR (1999) Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J Vasc Interv Radiol 10(4):463–471

    Article  PubMed  CAS  Google Scholar 

  17. Lokich JJ, Bothe A Jr, Benotti P, Moore C (1985) Complications and management of implanted venous access catheters. J Clin Oncol 3(5):710–717

    PubMed  CAS  Google Scholar 

  18. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S (2004) Risk factors for catheter-related thrombosis in cancer patients. Eur J Canc 40(15):2253–2259

    Article  CAS  Google Scholar 

  19. Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC (2008) Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 19(3):433–442

    Article  PubMed  CAS  Google Scholar 

  20. van Rooden CJ, Rosendaal FR, Barge RM, van Oostayen JA, van der Meer FJ, Meinders AE et al (2003) Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 123(3):507–512

    Article  PubMed  Google Scholar 

  21. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N et al (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17(2):289–296

    Article  PubMed  CAS  Google Scholar 

  22. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112(6):423–428

    PubMed  CAS  Google Scholar 

  23. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R et al (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75(2):251–253

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Clinical Trials Unit Kantonsspital St. Gallen.

Author information

Authors and Affiliations

  1. Department of Oncology–Haematology, Kantonsspital St. Gallen, Rorschacherstrasse, 9007, St. Gallen, Switzerland

    Felicitas Hitz, Aurelius Omlin, Salomé Riniker & Thomas Cerny

  2. Kantonsspital Bruderholz, Chirurgische Klinik, 4101, Bruderholz, Switzerland

    Andreas Zerz

  3. Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland

    Dirk Klingbiel

Authors
  1. Felicitas Hitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Klingbiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aurelius Omlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salomé Riniker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andreas Zerz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Cerny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felicitas Hitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hitz, F., Klingbiel, D., Omlin, A. et al. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol 91, 613–620 (2012). https://doi.org/10.1007/s00277-011-1343-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1343-8

Keywords

Search

Navigation